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S U M M A R Y
Objectives: To investigate the molecular epidemiology of Acinetobacter baumannii strains isolated from
different hospitals in Lebanon.
Methods: A total of 119 non-duplicate Acinetobacter strains were identiﬁed using matrix-assisted laser
desorption/ionization time-of-ﬂight mass spectrometry (MALDI-TOF MS) and partial rpoB gene
sequencing. Antibiotic susceptibility testing was performed by disc diffusion method and all identiﬁed
carbapenem-resistant isolates were investigated by PCR assays for the presence of the carbapenemase-
encoding genes. Multilocus sequence typing (MLST) and pulsed-ﬁeld gel electrophoresis (PFGE) were
used for molecular typing.
Results: Of the 119 A. baumannii isolates, 76.5% were resistant to carbapenems. The most common
carbapenemase was the OXA-23-type, found in 82 isolates. The study of population structure using MLST
revealed the presence of 30 sequence types (STs) including 18 new ones, with ST2 being the most
commonly detected, accounting for 61% of the isolates typed. PFGE performed on all strains of ST2
identiﬁed a major cluster of 53 isolates, in addition to three other minor clusters and ten unique proﬁles.
Conclusions: This study highlights the wide dissemination of highly related OXA-23-producing
carbapenem-resistant A. baumannii belonging to the international clone II in Lebanon. Thus, appropriate
infection control measures are recommended in order to control the geographical spread of this clone in
this country.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Acinetobacter baumannii is one of the most common opportu-
nistic Gram-negative bacteria associated with community-ac-
quired infections, outbreaks, and nosocomial infections,
particularly in critically ill patients. This bacterium is involved
in respiratory tract infections, bloodstream infections, skin and soft
tissue infections, urinary tract infections, and meningitis, leading
to increased rates of mortality and morbidity.1,2* Corresponding author. Tel.: +33 2 41 35 50 13; fax: +33 2 41 35 41 64.
E-mail address: makempf@chu-angers.fr (M. Kempf).
http://dx.doi.org/10.1016/j.ijid.2016.09.017
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Infections caused by A. baumannii are an increasing threat in
many countries. Indeed, this bacterium has a strong ability to resist
desiccation and to survive on inanimate surfaces. Moreover, the
prevalence of multidrug-resistant (MDR) isolates has increased
worldwide in recent decades,3,4 due to its ability to develop
multidrug resistance through either the acquisition of genetic
determinants such as plasmids, integrons, and transposons, or
through the acquisition of mutations leading to the modiﬁcation of
antibiotic targets, efﬂux pump expression, and membrane
permeability.5 As a consequence, the treatment of infections
caused by such isolates has become more and more difﬁcult, even
with most clinically available drugs, including tigecycline, colistin,
and carbapenems.1,4,6ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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Lebanese Society of Infectious Diseases showed that the percent-
age of resistance to imipenem among Acinetobacter spp increased
signiﬁcantly from 57.6% in 2011 to 84.5% in 2013.7 In A. baumannii,
carbapenem resistance was mostly associated with the production
of carbapenem-hydrolyzing class D b-lactamases (CHDLs), includ-
ing OXA-23, OXA-24, OXA-58, OXA-143, and OXA-235, in addition
to carbapenemases from classes B and A.6
Nowadays, understanding the molecular characteristics of
epidemic strains is the key strategy to track outbreaks and to
control the spread of A. baumannii, both in hospitals and in the
community.8,9 Several molecular typing methods have been
developed for this purpose. Among them, pulsed ﬁeld gel
electrophoresis (PFGE) and multilocus sequence typing (MLST)
have been the most frequently used and have represented the gold
standard methods to investigate strain clonality and the bacterial
population structure, respectively.10 Molecular epidemiological
studies have revealed A. baumannii outbreaks to have been caused
mainly by MDR strains belonging to the international clonal
complexes CC1, CC2, and CC3.8,11 In Lebanon, previous studies
have reported the predominance of carbapenem-resistant A.
baumannii strains belonging to the international clone II .12,13
The main objectives of this work were to investigate the
prevalence of carbapenem-resistant A. baumannii isolates (CRAb)
circulating in some Lebanese hospitals between 2013 and 2015,
and to characterize the common resistance mechanisms. The
population structure, as well as the genetic relatedness of CRAb
isolates, was also studied in order to track the evolution and the
clonality of these strains.
2. Materials and methods
2.1. Bacterial strain collection and identiﬁcation
A total of 119 non-replicate A. baumannii clinical isolates were
analyzed. These strains were collected between October 2013 and
December 2015 from the following hospitals in Lebanon: Tripoli
Governmental Hospital (TGH; 100 beds), Nini Hospital (NH;
120 beds), Makassed General Hospital (MGH; 150 beds), Saydet
Zgharta Hospital (SZH; 149 beds), Hanane Hospital (HH; 45 beds),
Al Youssef Medical Centre (YMC; 100 beds), Seblin Governmental
Hospital (SGH; 70 beds), and Dar Ajaza Hospital (DAH; 580 beds).
Isolates were sent to the Laboratory of Microbiology Health and
Environment (LMSE), Tripoli, Lebanon, and were stored at 80 8C.
Bacterial identiﬁcation was performed by matrix-assisted laser
desorption/ionization time-of-ﬂight mass spectrometry (MALDI-
TOF MS) using the Vitek MS (bioMe´rieux, Marcy l’Etoile, France),
and conﬁrmed at the species level by partial RNA polymerase
b-subunit (rpoB) gene sequencing, as described previously.13 For
each isolate, information on the sex and age of the patient, the
clinical specimen, and the type of ward were provided.
2.2. Antibiotic susceptibility testing and investigation of carbapenem
resistance mechanisms
Antibiotic susceptibility testing was performed by disc diffu-
sion method according to the recommendations of the European
Committee on Antimicrobial Susceptibility Testing (http://www.
eucast.org). A panel of 14 antibiotics was tested, including
ticarcillin, ticarcillin–clavulanic acid, piperacillin–tazobactam,
ceftazidime, imipenem, ciproﬂoxacin, amikacin, gentamicin,
tobramycin, trimethoprim–sulfamethoxazole, colistin, doxycy-
cline, tigecycline, and rifampicin. Carbapenem resistance was
conﬁrmed by determining minimum inhibitory concentration
(MICs) against imipenem and meropenem by Etest strips
(bioMe´rieux).Carbapenem-resistant isolates were investigated by PCR
assays for the presence of the carbapenemase-encoding genes
blaOXA-23-like, blaOXA-24-like, blaOXA-58-like, blaOXA-143, blaNDM, blaIMP,
and blaVIM.
12 Sequencing of the entire gene was performed on all
New Delhi metallo-b-lactamase (NDM)-positive isolates.
2.3. Epidemiological typing
2.3.1. Multilocus sequence typing (MLST)
MLST was performed according to the Pasteur scheme (http://
www.pasteur.fr/recherche/genopole/PF8/mlst/Abaumannii.html).
The internal fragments of seven housekeeping genes (fusA, pyrG,
rpoB, rplB, cpn60, gltA, and recA) were ampliﬁed, then puriﬁed and
sequenced using an ABI 3130XL DNA sequencer (Applied
Biosystems, Foster City, CA, USA). The allelic number and sequence
types (STs) were analyzed using the A. baumannii MLST database.
New STs were submitted and assigned by the Institut Pasteur MLST
database. The clustering of related STs (deﬁned as clonal
complexes, CCs) was analyzed using eBURST software (http://
eburst.mlst.net). A CC is deﬁned as a set of similar ST(s) having six
identical loci among seven, so a CC is formed by the founder ST and
its single locus variants (SLV).
2.3.2. Pulsed ﬁeld gel electrophoresis (PFGE)
A. baumannii DNA was digested with ApaI (TaKaRa, Dalian,
Liaoning Province, China) as a restriction enzyme. DNA fragments
were separated on 1% w/v agarose gels in 0.5 Tris/borate/
ethylenediaminetetraacetic acid (TBE) buffer at 14 8C using a CHEF
DRII apparatus (Bio-Rad) with 6 V/cm, pulsed from 3 to 20 s for
21 h; gels were stained with Gel Red. The Dice coefﬁcient was used
to calculate similarities, and the unweighted pair group method
using average linkages (UPGMA) was used for cluster analysis with
ﬁngerprinting II software (Bio-Rad, Marne La Coquette, France).
Isolates were considered to belong to the same PFGE clone if their
Dice similarity index was 80%.
3. Results
3.1. Bacterial strain collection and identiﬁcation
The 119 isolates analyzed in this study were collected from
seven hospitals situated in different regions in Lebanon: North of
Lebanon, Beirut, and Mount of Lebanon. Forty-eight isolates were
from Tripoli Governmental Hospital (Tripoli, North of Lebanon),
40 from Nini Hospital (Tripoli, North of Lebanon), 21 from
Makassed General Hospital (Beirut), four from Saydet Zgharta
Hospital (Zgharta, North of Lebanon), two from each of Hanane
Hospital (Tripoli, North of Lebanon) and Al Youssef Medical Centre
(Akkar, North of Lebanon), and one from each of Dar Ajaza (Beirut)
and Seblin Governmental Hospital (Seblin, Mount of Lebanon). The
isolates were mostly recovered from the respiratory tract (n = 35;
29%) and skin and soft tissue (n = 33; 28%), followed by urine
(n = 14; 12%), blood (n = 9; 7.6%), and vascular catheters (n = 6; 5%).
Of note, 19 (13.4%) patients were asymptomatically colonized
(Table 1).
3.2. Antibiotic susceptibility testing and investigation of carbapenem
resistance mechanisms
Antibiotic susceptibility testing showed that the A. baumannii
isolates analyzed were MDR. Indeed, most of them were resistant
to b-lactams, aminoglycosides, ciproﬂoxacin, and doxycycline.
However, only four isolates were resistant to rifampicin and one
isolate to tigecycline, while colistin and tigecycline maintained
their activity against all isolates. Among the isolates, 91 (76.5%)
showed an imipenem-resistant phenotype. Etest results conﬁrmed
Table 1
Characteristics of Acinetobacter baumannii isolates









1 M NA Tracheal aspirate 2013 Tripoli TGH ICU S - 698 S
2 F 65 Rectal swab 2013 Tripoli NH ICU R OXA-23 2 2
3 F 76 Tracheal aspirate 2013 Tripoli NH ICU R OXA-23 2 2
4 M 18 Wound 2013 Tripoli TGH IM R OXA-23 2
5 F NA Broncho-tracheal lavage 2013 Tripoli TGH IM R OXA-23 2 2
6 M NA Wound 2013 Tripoli TGH IM R OXA-23 2 2
7 M 66 Tracheal aspirate 2013 Tripoli TGH IM R OXA-23 2 2
8 M NA Wound 2013 Tripoli TGH IM R OXA-23 2 2
9 M 45 Catheter 2013 Tripoli HH NA R OXA-23 2
10 F 81 Rectal swab 2014 Tripoli NH ICU R OXA-23 2 2
11 F 39 Wound 2014 Tripoli TGH IM R OXA-23 2 2
12 M NA Broncho-tracheal lavage 2014 Tripoli TGH ICU R OXA-23 2 2
13 M NA Blood 2014 Tripoli TGH IM R NDM-1 85 85
14 M 82 Rectal swab 2014 Tripoli NH IM S - 600 2
15 F NA NA 2014 Tripoli HH NA R OXA-23 2 2
16 F 86 Tracheal aspirate 2014 Tripoli NH ICU R OXA-23 2 2
19 F 23 Urine 2014 Tripoli NH OP S - 701 S
20 F 84 Nasal swab 2014 Tripoli NH ICU R OXA-23 2 2
21 M 21 Wound 2014 Tripoli TGH IM R OXA-23 2 2
22 F NA Sputum 2014 Tripoli TGH ICU R OXA-23/OXA-24 2 2
23 M 60 NA 2014 Zgharta SZH NA S - 2 2
24 M NA Blood 2014 Tripoli TGH ICU S - 702 S
26 F NA Wound 2014 Tripoli TGH IM R OXA-23 2 2
27 M 83 Rectal swab 2014 Tripoli NH IM S - 2 2
28 M NA Sputum 2014 Tripoli TGH ICU R OXA-23 2 2
29 F 38 Urine 2014 Tripoli NH OP S - 704 S
30 F NA Catheter 2014 Tripoli TGH ICU S - 702 S
33 M NA Sputum 2014 Tripoli TGH ICU S - 702 S
34 F 78 Urine 2014 Tripoli NH NA S - 46 S
35 M NA NA 2014 Zgharta SZH NA R OXA-23 705 S
36 M NA Sputum 2014 Tripoli TGH NA S - 702 S
38 M 44 Tracheal aspirate 2014 Tripoli NH ICU R OXA-23 2 2
39 M NA Broncho-tracheal lavage 2014 Tripoli TGH IM R OXA-23 2 2
40 M 84 Urine 2014 Tripoli NH IM S - 2 2
43 M 27 Rectal swab 2014 Tripoli NH ICU S - 25 25
44 M NA Wound 2014 Tripoli TGH IM R OXA-143 2 2
45 F 60 Wound 2014 Tripoli TGH ICU R OXA-23 2 2
46 M NA Wound 2014 Tripoli TGH IM R OXA-23 2 2
47 M NA Wound 2014 Tripoli TGH IM R OXA-23 2 2
48 F NA Wound 2014 Tripoli TGH IM R OXA-23 2 2
50 M NA Sputum 2014 Tripoli TGH ICU R OXA-23 2 2
51 M NA Blood 2014 Tripoli TGH ICU R OXA-23 2 2
53 M 65 Rectal swab 2014 Tripoli TGH ICU S - 52 S
54 F NA Wound 2014 Tripoli TGH OP S - 690 S
55 M 81 Bed swab 2014 Seblin SGH ICU R OXA-23 706 S
56 M 77 Wound 2014 Tripoli NH ICU S - 25 25
58 M NA Wound 2014 Tripoli TGH IM R OXA-23 2 2
59 F NA Urine 2014 Tripoli TGH IM R OXA-23/OXA-24 2 2
60 M 47 Pus 2014 Tripoli NH OP S - 1 1
61 M 82 Sputum 2014 Zgharta SZH NA R OXA-23 2 2
62 M 23 Wound 2014 Tripoli TGH IM R OXA-23 2 2
63 M 64 LCR 2014 Tripoli NH ICU S - 25 25
64 F NA Wound 2014 Tripoli TGH IM R OXA-23 2 2
65 F 69 Tracheal aspirate 2015 Tripoli NH ICU R OXA-23 2 2
66 F NA Wound 2015 Tripoli TGH ICU R NDM-1 85 85
67 M 75 Pus 2015 Tripoli NH ICU R OXA-23 707 S
68 M NA Pus 2015 Tripoli TGH IM R NDM-1 708 S
69 M 75 Nasal swab 2015 Tripoli TGH ICU R OXA-23/OXA-58 2 2
70 M 75 Rectal swab 2015 Tripoli NH ICU R OXA-23 2 2
71 NA NA Pus 2015 Zgharta SZH NA R OXA-23 2 2
72 F 18 Catheter 2015 Tripoli NH ICU R OXA-23 2 2
73 M 84 Rectal swab 2015 Tripoli NH ICU R OXA-23 2 2
74 M 75 Nasal swab 2015 Tripoli NH ICU R OXA-23 2 2
75 F 18 Tracheal aspirate 2015 Tripoli NH ICU R OXA-23 2 2
76 M 82 Rectal swab 2015 Tripoli NH ICU S - 2 2
77 F 69 Axillary swab 2015 Tripoli NH ICU R OXA-23 2 2
78 F 63 Urine 2015 Tripoli NH ICU S - 807 S
79 M 84 Urine 2015 Tripoli NH ICU S - 25 25
80 M NA Catheter 2015 Tripoli NH ICU S - 25 25
81 F 78 Urine 2015 Beirut DAH IM R OXA-23/OXA-24 2 2
82 M NA Blood 2015 Tripoli TGH ICU S - 424 33
83 M NA Tracheal aspirate 2015 Tripoli TGH ICU R NDM-1 708 S
84 M 70 Blood 2014 Beirut MGH IM R OXA-23 2 2
85 M 64 Tracheal aspirate 2014 Beirut MGH IM R OXA-23 2 2
86 M 66 Tracheal aspirate 2015 Beirut MGH IM R OXA-23 2 2
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87 M 82 Tracheal aspirate 2014 Beirut MGH ICU R OXA-23/OXA-24 711 S
88 F 81 Tracheal aspirate 2015 Beirut MGH IM R OXA-23 2 2
89 M 83 Tracheal aspirate 2015 Beirut MGH IM R OXA-23 2 2
90 F 83 Pus 2015 Beirut MGH IM R OXA-23 570 2
91 F 87 Blood 2015 Beirut MGH IM R OXA-23/OXA-24 715 S
92 M 19 Tracheal aspirate 2015 Beirut MGH ICU R OXA-23 570 2
93 F 67 Blood 2015 Beirut MGH CCU R OXA-23 570 2
94 M 58 Tracheal aspirate 2015 Beirut MGH CCU R OXA-23 600 2
95 M 26 Tracheal aspirate 2014 Beirut MGH IM R OXA-23 2 2
96 F 71 Tracheal aspirate 2015 Beirut MGH SURG R OXA-23 570 2
97 M 63 Tracheal aspirate 2015 Beirut MGH IM R OXA-23 2 2
98 M 31 Pus 2015 Beirut MGH IM R OXA-23 2 2
99 M 79 Sputum 2015 Beirut MGH CCU R OXA-23 2 2
100 F 47 Sputum 2015 Beirut MGH IM R OXA-23 713 2
101 F 74 Tracheal aspirate 2015 Beirut MGH IM R OXA-23 2 2
102 F 84 Blood 2015 Beirut MGH CCU R OXA-23/OXA-24 714 S
103 F 84 Tracheal aspirate 2015 Beirut MGH ICU R OXA-23 2 2
104 F 93 Tracheal aspirate 2015 Beirut MGH ICU R OXA-23 600 2
105 F 50 Urine 2015 Tripoli NH IM S - 808 S
106 M 42 Pus 2015 Tripoli NH IM R OXA-23 1 1
107 M NA Wound 2015 Tripoli TGH IM R OXA-23 85 85
108 M NA Wound 2015 Tripoli TGH IM R OXA-24 636 S
109 M 74 Rectal swab 2015 Tripoli NH ICU R OXA-23 2 2
110 M 65 Wound 2015 Akkar YMC NA R OXA-23 2 2
111 M 55 Urine 2015 Tripoli NH IM R OXA-23 2 2
112 F NA Catheter 2015 Tripoli TGH IM S - 193 S
113 F 38 Wound 2015 Tripoli TGH IM R OXA-23 2 2
114 F NA Pus 2015 Tripoli TGH ICU R OXA-23 2 2
115 F NA Catheter 2015 Tripoli TGH ICU R OXA-23 2 2
116 M 5 Urine 2015 Tripoli NH OP S - 809 S
117 F 19 Urine 2015 Tripoli NH OP S - 810 S
118 M NA Urine 2015 Akkar YMC NA S - 811 S
119 M 80 Wound 2015 Tripoli NH OP R OXA-23 2 2
120 F NA Broncho-tracheal
lavage
2015 Tripoli TGH IM R OXA-23 2 2
121 F 71 Rectal swab 2015 Tripoli NH CCU R OXA-23 2 2
122 M NA Wound 2015 Tripoli TGH IM R OXA-23 2 2
123 F NA Broncho-tracheal
lavage
2015 Tripoli TGH ICU R OXA-24 2 2
124 F 32 Blood 2015 Tripoli NH ICU R OXA-23 2 2
125 M NA Broncho-tracheal
lavage
2015 Tripoli TGH ICU R OXA-23 2 2
126 F 75 Pus 2015 Tripoli NH P R OXA-23 2 2
127 M 46 Catheter 2015 Tripoli NH ICU R OXA-23 2 2
128 M 46 Nasal swab 2015 Tripoli NH ICU R OXA-23 25 25
129 F NA Wound 2015 Tripoli TGH NA R OXA-23 2 2
130 M NA Urine 2015 Tripoli TGH IM R OXA-24 812 S
CC, clonal complex; CCU, cardiac care unit; DAH, Dar Ajar Hospital; F, female; HH, Hanane Hospital; ICU, intensive care unit; IM, internal medicine; CSF, cerebrospinal ﬂuid; M,
male; MGH, Makassed General Hospital; NA, not assigned; NH, Nini Hospital; OP, outpatient; P, paediatric; SGH, Seblin Governmental Hospital; ST, sequence type; SURG,
surgery; SZH, Sayedt Zgharta Hospital; TGH, Tripoli Governmental Hospital; YMC, Al Youssef Medical Centre.
a Phenotype: ‘R’ resistant or ‘S’ susceptible to carbapenems.
b S: singleton.
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meropenem were >32 mg/l. Carbapenemase determinants were
detected in all carbapenem-resistant isolates. blaOXA-23-like was the
most common gene found (n = 76; 83.5%). Furthermore, three
blaOXA-24-like and four blaNDM-1 were detected. Of note, six isolates
carried both blaOXA-23-like and blaOXA-24-like genes and one isolate
carried both blaOXA-23-like and blaOXA-58-like genes. Finally, blaOXA-
143-like was found in one isolate.
3.3. Epidemiological typing
3.3.1. Multilocus sequence typing
MLST was performed on all isolates. As a result, 30 STs including
18 new ones were identiﬁed in this study. ST2 was the most
commonly observed (73/119 isolates), accounting for 61% of the
isolates typed. Other less common STs were ST25 (six isolates) and
ST570 (four isolates), followed by ST85, ST600 (both with three
isolates) and ST1 (two isolates). The remaining STs were foundsporadically in this collection (Table 1). Based on eBURST analysis,
ST2 as well as ST570, ST600, and ST713 (which are SLVs of ST2)
belonged to CC2, while ST706 was a double locus variant (DLV) of
ST2. Furthermore, ST1, ST25, ST85, and ST424 (a SLV of ST33)
belonged to CC1, CC25, CC85, and CC33, respectively. ST690 was a
DLV of CC25, and ST193 and ST702 were DLVs of CC33. Finally,
ST46 was a SLV of ST622, and ST715 was a SLV of ST636. The
remaining STs were singletons, since they did not share any
homology with a known ST in the database (Fig. 1).
3.3.2. PFGE analysis
Based on the above MLST results, all strains of ST2 were selected
for PFGE typing in order to investigate their clonality. Overall,
73 strains were analyzed. As shown in Fig. 2, PFGE revealed the
presence of four clusters with two or more isolates and 10 unique
proﬁles. The major cluster (cluster C) comprised 52 carbapenem-
resistant isolates harbouring the blaOXA-23-like gene with or without
either the blaOXA-24-like gene or the blaOXA-58-like gene, as well as one
Fig. 1. Population snapshot analysed by eBURST on 836 sequences present in the MLST Pasteur database (05/05/2016). Red points and circles show sequence types identiﬁed
in this study and the most important clonal complexes, respectively.
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these strains displayed identical PFGE patterns, although they
were isolated from different hospitals in different locations, mainly
in Tripoli (40 isolates), Beirut (nine isolates), Zgharta (three
isolates), and Akkar (one isolate). The second cluster (cluster A)
contained ﬁve isolates producing the blaOXA-23-like gene that were
recovered from two distinct hospitals in Tripoli (Table 1).
Furthermore, the OXA-23-producing isolates (numbers 5, 85,
and 103) that were isolated in Tripoli (TGH) and Beirut (MGH)
belonged to cluster B. Finally, cluster D contained two carbape-
nem-resistant strains harbouring the blaOXA-23-like gene isolated
from the same hospital (NH).
4. Discussion
A. baumannii is the most common opportunistic pathogen
causing nosocomial infections, particularly respiratory tract
infections in intensive care units among critically ill patients.14
Nowadays, the excessive use of antimicrobial agents in and outside
hospitals may be an important cause of the isolation of MDR A.
baumannii strains around the world.15–18 The major problem is
that infections caused by such isolates are associated with greater
morbidity and greater healthcare costs.19,20
The current survey was conducted in different hospitals
distributed across the country, with isolates mostly being
recovered from two main hospitals in Tripoli, North of Lebanon
and one main hospital in Beirut. A total of 119 A. baumannii clinical
strains were included in this study to evaluate antibiotic resistance
phenotypes and molecular epidemiological features. These strains
were isolated from nosocomial infections, but also from infections
present at the time of admission to the hospitals, and a number of
patients were only colonized.
Antibiotic susceptibility testing showed a very serious situa-
tion. Of all A. baumannii isolates, 76.5% were carbapenem-resistant.
This rate is higher than those reported in other countries such as
China, Saudi Arabia, Greece, Italy, and the USA, where reportedrates were 29.4%, 69%, 57.4%, 45.7% and 34% respectively.9,14,21–23
Interestingly, in previous studies in Lebanon, the rate of CRAb
isolates was signiﬁcantly different.13,24 Moreover, 60.5% of the
isolates presented here were resistant to aminoglycosides and 87%
were resistant to ﬂuoroquinolone, while tigecycline and colistin
maintained their activity against all isolates.
The blaOXA-23 gene is considered a signiﬁcant cause of
carbapenem resistance in A. baumannii worldwide.25 This study
revealed that carbapenem resistance in A. baumannii was also
mainly associated with this gene. The present ﬁndings are similar
to those reported previously from Lebanon and other coun-
tries.13,22,26–28 Additionally, the co-occurrence of two OXA-type
genes has also been reported in A. baumannii.22,29 In the present
study, the coexistence of either blaOXA-23 and blaOXA-24 or blaOXA-23
and blaOXA-58 was found in seven isolates. Moreover, the ﬁrst
description of a blaOXA-143-like strain is reported here, which was
isolated in 2014 from a wound sample of a female patient admitted
to TGH. Alarmingly, since the ﬁrst description in Lebanon of a
blaNDM-1-positive A. baumannii
30 and Acinetobacter pittii,31 four
more isolates were found in this study.
Epidemiological tools are important to track outbreaks and to
investigate strain relatedness in order to control the spread of
MDR isolates. The evolutionary history and the dynamic spread
of A. baumannii in this study were investigated by MLST. The data
revealed that CC2 (ST2, ST570, ST600, ST713) was the main clonal
complex found in Lebanon over recent years. Interestingly,
almost all of these isolates were resistant to carbapenems, which
is in agreement with previous studies that have used MLST for
epidemiological characterization of A. baumannii.8,12,21,32,33 In
Lebanon, even if different clones and STs have been described,
CC2 and particularly ST2 appear to be widely distributed. The
capacity for bioﬁlm formation, adherence to abiotic surfaces, and
acquisition of antimicrobial resistance determinants could be the
main factors that enhance the spread and the persistence of this
CC in the hospital setting, as has been described previously.34
Moreover, CC1 and CC25 have also been responsible for several
Fig. 2. Dendrogram illustrating the PFGE patterns of Acinetobacter baumannii isolates.
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emerging clones.8,32,35 Strains belonging to these clones were
detected in the present study. However, these strains, with the
exception of one isolate (ST25), were all susceptible to
carbapenems, which is not consistent with the results of Rafei
et al., who found only carbapenem-resistant strains belonging to
CC1 and CC25 in Lebanon.13 These ﬁndings may highlight the
potential role of hospitals as reservoirs for carbapenem resis-
tance genes. Another new emerging clone, ST85 (CC85), which
has long been associated with NDM-1,13,36,37 was also detected
in three isolates. Among them, two were NDM-1-producers and
the remaining isolate was an OXA-23-producer. Of note, the
detection of several new STs may support and highlight the
continuous clonal evolution of A. baumannii. This diversity may
be due to several mechanisms, such as mutations or the transfer
and mobilization of genetic elements including insertion
sequences.38As shown in Table 1, 73 strains belonging to ST2 were further
selected for PFGE typing. Around 72.6% (n = 53) of them belonged
to the same PFGE cluster, which appeared to be a predominant
clone in Lebanon. Noteworthy, among this clone, several strains
sharing identical PFGE patterns were detected, although they were
not isolated in the same hospital or in the same location, such as
strains 69, 71, and 75 (Fig. 2). This ﬁnding may suggest a possible
inter-hospital transmission of these carbapenem-resistant strains.
On the other hand, the presence of identical strains in the same
hospital (Fig. 2) may also highlight the existence of pseudo
outbreaks. Thus, early surveillance is warranted and the develop-
ment of appropriate infection control measures (environmental
and equipment cleaning and disinfection, implementation of a
hand hygiene programme for healthcare workers, isolation of
patients with MDR A. baumannii, early screening of the hospital-
ized patients, genotyping of the isolated strains, etc.) is recom-
mended in order to eradicate the geographical spread of this clone.
A.A. Atrouni et al. / International Journal of Infectious Diseases 52 (2016) 29–36 35MLST approaches have been used widely for the genotyping of
A. baumannii due to their reproducibility and portability, facilitat-
ing comparisons between laboratories. Although MLST is an
expensive typing method, it provides good information on the
molecular epidemiology across different hospitals and loca-
tions.10,39 Even if it is not suitable for inter-laboratory comparison,
PFGE allows the investigation of outbreaks due to its high
discriminatory power. PFGE analysis showed that the majority
of the isolates belonging to ST2 were highly related, which is in
agreement with the ﬁndings of previous studies.12,39 However, it is
recommended that both techniques are used when testing a high
number of strains isolated from different locations at different time
points.
Finally, although the clinical isolates collected may be limited,
these data provide a global view on the molecular epidemiology of
CRAb circulating in Beirut and the North of Lebanon during recent
years. Of note, A. baumannii has evolved as a global pathogen
causing community-acquired infections and war and natural
disaster-related infections.40 Thus, there is no doubt that the
overall epidemiology of A. baumannii in Lebanon could be highly
inﬂuenced by the Syrian War, since several wounded Syrian
refugees have been hosted in different Lebanese cities and
admitted to different Lebanese hospitals.13 Therefore, further
research is needed including more strains from other hospitals
situated in different governorates in order to ensure the continu-
ous surveillance of these MDR organisms in Lebanon.
In conclusion, this study provides evidence of the wide
dissemination of OXA-23-producing carbapenem-resistant A.
baumannii belonging to international clone II in Lebanon. Although
PFGE results did not always correlate with MLST, both techniques
remain nevertheless useful for the investigation of the molecular
epidemiology and clonal spread of A. baumannii.
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